MONT-SAINT-GUIBERT, Belgium—Celyad SA announced recently that a summary of preclinical work with NKR-2, its CAR-T cell therapy being evaluated in the THINK trial, was published in a special report in Future Oncology. The report, titled “Exploiting Natural Killer Group 2D Receptors for CAR-T cell therapy,” details the potency of CAR-T NKR-2 cells in vitro against human cancer cell lines of leukemia, colorectal and pancreatic cancer as well as new data showing that CAR-T NKR-2 cells can challenge established pancreatic cancer xenografts in humanized mouse models.

 

Dr. Christian Homsy, CEO of Celyad, said that “We are pleased to provide further preclinical evidence validating our approach in the THINK trial, in which we aim to demonstrate the potential of CAR-T NKR-2 cells as a disruptive technology in the treatment of cancer.”